The landscape for GLP-1 weight loss drugs underwent a significant shift this week as federal regulators launched legal actions against unapproved sellers while international health experts released major findings on long-term efficacy. The U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) are taking decisive steps to restrict the sale of non-approved versions of popular medications like semaglutide and tirzepatide. These developments come as the World Health Organization (WHO) prepares new global guidelines for obesity treatment based on extensive reviews of these blockbuster drugs.
The surge in demand for weight loss treatments has created a crowded market where pharmaceutical giants like Novo Nordisk and Eli Lilly compete with telehealth companies offering less expensive, compounded alternatives. While these medications have shown remarkable results in clinical trials, the recent crackdown highlights growing concerns regarding patient safety and the quality of unapproved formulations. Federal officials are now focusing on marketing practices that may mislead consumers about the risks and regulatory status of these powerful treatments.
FDA and Justice Department Target Unapproved Sellers
Federal authorities have significantly escalated their enforcement efforts against companies marketing unapproved versions of GLP-1 medications. On Friday, Feb. 6, 2026, the FDA announced it would use all available compliance tools to address public health concerns and unsubstantiated claims made by online marketers. As part of this initiative, Mike Stuart, general counsel for the U.S. Health Department, confirmed that his office referred the telehealth firm Hims & Hers to the Justice Department for potential violations of the federal Food, Drug, and Cosmetic Act.
The referral follows concerns that some companies have been selling “copycat” versions of drugs like Wegovy and Ozempic without undergoing the rigorous FDA review process required for safety and effectiveness. Hims & Hers recently began offering a compounded semaglutide option for a starting price of $49 per month, which Novo Nordisk characterized as “illegal mass compounding.” In response to the federal pressure and the threat of legal action, Hims & Hers shares dropped 14%, and the company reportedly decided to stop offering its compounded weight loss pill.
WHO Commissioned Reviews Confirm Efficacy of GLP-1s
While regulators handle legal enforcement, the scientific community is providing a clearer picture of how these drugs perform over time. Three new Cochrane reviews, commissioned by the WHO and released on Feb. 11, 2026, found that GLP-1 receptor agonists lead to clinically meaningful weight loss. The most effective of the group, tirzepatide (sold as Zepbound and Mounjaro), resulted in an average weight reduction of approximately 16% after 12 to 18 months of treatment.
Semaglutide, the active ingredient in Wegovy and Ozempic, produced an average weight loss of about 11% over 24 to 68 weeks. Liraglutide, an older daily injection, showed more modest results with an average loss of 4% to 5%. Despite these “impressive” results, researchers noted that most trials were funded by the drug manufacturers themselves. This industry involvement has led to calls for more independent research to assess long-term safety and cardiovascular health, particularly in lower-risk individuals.
Novo Nordisk and Eli Lilly Spark Price War
The pharmaceutical market is also seeing a shift in pricing as manufacturers respond to political pressure and competition from compounding pharmacies. Following discussions with the administration of President Donald Trump, Novo Nordisk announced significant price cuts for cash-paying patients. The drugmaker is now offering the initial two monthly doses of Wegovy and Ozempic for $199, with the regular price for other self-pay tiers dropping from $499 to $349 per month.
This pricing strategy aims to make the drugs more accessible to Americans who are willing to buy directly from the manufacturer and forgo insurance. Additionally, Novo Nordisk and Eli Lilly secured a major deal with the federal government to expand their reach in the Medicare and Medicaid markets. Under this agreement, the average monthly cost for these medications is expected to drop to approximately $250 over the next two years, with potential tablet versions starting as low as $149 if they receive future approval.
Safety Risks of Compounded Weight Loss Drugs
The FDA continues to warn the public about the hidden dangers associated with unapproved or compounded versions of GLP-1 drugs. Unlike FDA-approved medications, compounded versions are not reviewed for quality or consistency. The agency has received reports of serious adverse events, including intense nausea, vomiting, and abdominal pain, often linked to incorrect dosing or the use of improper “salt” forms of the active ingredients, such as semaglutide sodium.
Some patients have required hospitalization after taking doses that far exceeded the approved labeling or after using products with inadequate quality controls. As the national supply of approved GLP-1 medications begins to stabilize, the FDA is clarifying policies that will likely phase out the widespread use of compounded alternatives by later this year. Experts recommend that patients only use medications sourced from authorized manufacturers to ensure they are receiving the correct dose and the evaluated active ingredients.
